Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$47.6 million.

  • Anika Therapeutics' Income towards Parent Company rose 103.01% to $846,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 56.50%. This contributed to the annual value of -$47.6 million for FY2024, which is 39.97% up from last year.
  • As of FY2024, Anika Therapeutics' Income towards Parent Company stood at -$47.6 million, which was up 39.97% from -$79.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Income towards Parent Company registered a high of $6.7 million during FY2021, and its lowest value of -$79.2 million during FY2023.
  • Over the past 3 years, Anika Therapeutics' median Income towards Parent Company value was -$47.6 million (recorded in 2024), while the average stood at -$47.9 million.
  • As far as peak fluctuations go, Anika Therapeutics' Income towards Parent Company surged by 127.78% in 2021, and later slumped by 364.44% in 2023.
  • Yearly analysis of 5 years shows Anika Therapeutics' Income towards Parent Company stood at -$24.0 million in 2020, then soared by 127.78% to $6.7 million in 2021, then crashed by 356.03% to -$17.1 million in 2022, then tumbled by 364.44% to -$79.2 million in 2023, then spiked by 39.97% to -$47.6 million in 2024.